Leflunomide for MEN-1 related neuroendocrine tumors
Part of Cancer, Genetic & congenital, Hormones & metabolism clinical trials.
This trial tests if leflunomide, a medication usually used for arthritis, can shrink or slow the growth of neuroendocrine tumors in people with MEN-1 gene mutations. It is for patients whose tumors have worsened after standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a neuroendocrine tumor with an MEN-1 gene mutation.
- Your tumor cannot be removed by surgery and has continued to grow after at least one standard treatment.
- You have at least one tumor that can be measured on a scan.
- You are in fairly good health (able to do light activity) and your blood counts, liver, and kidney tests are within safe limits.
- You have not had cancer treatment, major surgery, or been in another clinical trial in the past 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted therapy (Surufatinib) and chemotherapy (Temozolomide and S-1) as a first treatment for advanced neuroendocrine tumors that have not been treated before. It aims to see if this drug combo is safe and effective.
This trial tests a combination of two drugs (Luvometinib and Serplulimab) for people with NF2 (Neurofibromatosis type 2) who have growing brain tumors (vestibular schwannoma or meningioma) that cannot be safely removed with surgery. The goal is to see if this drug combination can shrink or slow the growth of these tumors.
This trial tests a new drug called FTL001 for people with advanced solid tumors that have not improved with standard therapy. The goal is to see if it is safe and how well it works.
This Phase 1 trial studies whether leflunomide can slow or control advanced (metastatic) cancers in people whose tumors have specific PTEN changes or who have HER2-negative breast cancer. It’s primarily a safety-and-dosing study, but it may offer benefit if your cancer matches the tumor marker requirements.
This trial tests a daily capsule called semetinib for adults with type 1 neurofibromatosis (NF1) who have at least one measurable tumor. It aims to shrink or slow tumor growth, especially for tumors that can be surgically removed.
This trial tests a new experimental drug called LNF1901 for people with advanced cancers that have not responded to or cannot tolerate standard treatments. It aims to see if the drug is safe and effective.
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.